Across TCGA pan-cancer cohorts, CREBRF Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CREBRF data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CREBRF Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CREBRF expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, LUAD, and SARC are the cancer types where CREBRF Mutation most reproducibly stratifies survival.